Browse > Article

Treatment Outcome of Locally Advanced Non-small Cell Lung Cancer  

Lee, Heui-Kwan (Department of Radiation Oncology, Chonbuk National University Hospital)
Lee, Sun-Young (Department of Radiation Oncology, Chonbuk National University Hospital)
Kim, Jung-Soo (Department of Radiation Oncology, Chonbuk National University Hospital)
Kwon, Hyoung-Cheol (Department of Radiation Oncology, Chonbuk National University Hospital)
Publication Information
Radiation Oncology Journal / v.24, no.4, 2006 , pp. 237-242 More about this Journal
Abstract
$\underline{Purpose}$: We evaluated retrospectively the outcome of locally advanced non-small cell lung cancer patients treated with definitive radiotherapy to find out prognostic factros affecting survival. $\underline{Materials\;and\;Methods}$: 216 cases of stage IIIB non-small cell lung cancer were with treated radiotherapy at our Hospital between 1991 to 2002 and reviewed retrospectively. Cases were classified by mode of treatment and response to treatment. Patients showing complete response or partial response to treatment were included in the "response group", while those showing stable or progressive cancer were included in the "non-response group". $\underline{Results}$: 30 patients completed the planned radiotherapy treatments and 39 patients completed combined treatments or chemoradiotherapy. Median survival was 4.6 months for patients treated with radiotherapy and 9.9 months for those undergoing combined radiotherapy and chemotherapy. Survival rates for the first year were 13.3% with radiotherapy and 35.9% with chemoradiotherapy. In the second year, 3.3% of the radiotherapy patients survived and 20.5% of the patients receiving chemoradiotherapy survived. By the third year, 15.4% of the patients receiving the combined treatments survived. None of the patients treated with radiotherapy alone lived to the third year, however. Overall survival was significantly different between the radiotherapy patients and the combined chemoradiotherapy patients (p<0.001). In the response group, median survival was 7.2 months with radiotherapy and 16.5 months with combined therapy. In the non-response group, median survival was 4.4 months with radiotherapy and 6.7 months with combined treatments. Severe acute complications (grade 3) occurred in 2 cases using radiotherapy, and in 7 cases using combined therapy. $\underline{Conclusion}$: When the patients with stage IIIB non-small cell lung cancer received chemoradiotherapy, treatment response rate and overall survival was greater than with radiation alone.
Keywords
Non-small cell lung carcinoma; Radiotherapy; Survival;
Citations & Related Records
연도 인용수 순위
  • Reference
1 The World Health Organization (WHO). The World Health Report; 2003
2 World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48; 1979
3 Miller AB, Hogestraeten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214   DOI   ScienceOn
4 Ahn SJ, Chung WK, Nah BS, Nam TK, Kim YC, Park KO. Outcomes after radiotherapy in inoperable patients with squamous cell lung cancer. J Korean Soc Ther Radiol Oncol 2001;19:216-223   과학기술학회마을
5 Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the pattern of failure in patients with unresectable non- oat cell carcinoma of the lung treated with definitive radiotherapy: report by the Radiation Therapy Oncology Group. Cancer 1987;59:1874-1881   DOI   ScienceOn
6 Chang SH, Lee KJ, Lee SN. The results of definitive radiation therapy and the analysis of prognostic factors for non-small cell lung cancer. J Korean Soc Ther Radiol Oncol 1998;16: 409-423   과학기술학회마을
7 Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-423   DOI
8 Perez CA, Stanly K, Rubin P, Kramer S, Brady LW, Marks JE. Patterns of tumor recurrence after definitive irradiation for inoperable non-oat cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1980;6:987-994   DOI   ScienceOn
9 Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 1995;76:593-601   DOI   ScienceOn
10 Curran WJ, Scott C, Langer R, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:2499
11 Ministry of Health and Welfare. 2002 Annual Report of the Korea Central Cancer Registry (Published in 2003)
12 Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-945   DOI   ScienceOn
13 Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-364   DOI   ScienceOn
14 Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta- analysis. Ann Intern Med 1996;125:723-729   DOI   ScienceOn
15 Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524- 530   DOI   ScienceOn
16 Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699   DOI